|Bid||12.12 x 50000|
|Ask||0.00 x 81200|
|Day's Range||12.49 - 14.76|
|52 Week Range||2.06 - 14.76|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biotech Dynavax Technologies (NASDAQ: DVAX) had a terrific Thursday on the stock market. Thursday morning, Valneva announced that the committee for medicinal products for human use (CHMP) advising the European Medicines Agency (EMA) has recommended the jab be granted marketing authorization as a primary shot for adults 18 to 50 years old. The next step is for the European Commission (EC) to review the CHMP's recommendation and make a decision.
Valneva's COVID-19 vaccine was endorsed by the European Medicines Agency (EMA) on Thursday, although the French company's contract with the European Commission to supply the dose hangs in the balance. Valneva has been trying to salvage the deal with the European Commission after its vaccine programme was hit by delays in its marketing application due to requests from the EMA for more information.
Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.